These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. Dejgaard TF; Knop FK; Tarnow L; Frandsen CS; Hansen TS; Almdal T; Holst JJ; Madsbad S; Andersen HU BMJ Open; 2015 Apr; 5(4):e007791. PubMed ID: 25838513 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study. Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614 [TBL] [Abstract][Full Text] [Related]
10. Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. Gudbergsen H; Henriksen M; Wæhrens EE; Overgaard A; Bliddal H; Christensen R; Boesen MP; Knop FKK; Astrup A; Rasmussen MU; Bartholdy C; Daugaard C; Bartels EM; Ellegaard K; Heitmann BL; Kristensen LE BMJ Open; 2019 May; 9(5):e024065. PubMed ID: 31061017 [TBL] [Abstract][Full Text] [Related]
11. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ; Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120 [TBL] [Abstract][Full Text] [Related]
12. Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis - Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue. Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Karsdal MA; Brockbank S; Cruwys S Biomed Pharmacother; 2019 Mar; 111():926-933. PubMed ID: 30841472 [TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Bizino MB; Jazet IM; de Heer P; van Eyk HJ; Dekkers IA; Rensen PCN; Paiman EHM; Lamb HJ; Smit JW Diabetologia; 2020 Jan; 63(1):65-74. PubMed ID: 31690988 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. Idorn T; Knop FK; Jørgensen M; Jensen T; Resuli M; Hansen PM; Christensen KB; Holst JJ; Hornum M; Feldt-Rasmussen B BMJ Open; 2013; 3(4):. PubMed ID: 23624993 [TBL] [Abstract][Full Text] [Related]
15. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060 [TBL] [Abstract][Full Text] [Related]
16. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study). Jorsal A; Wiggers H; Holmager P; Nilsson B; Nielsen R; Boesgaard TW; Kumme A; Møller JE; Videbæk L; Kistorp C; Gustafsson I; Tarnow L; Flyvbjerg A BMJ Open; 2014 May; 4(5):e004885. PubMed ID: 24844271 [TBL] [Abstract][Full Text] [Related]
17. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR; Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334 [TBL] [Abstract][Full Text] [Related]
18. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X; Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263 [TBL] [Abstract][Full Text] [Related]
19. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502 [TBL] [Abstract][Full Text] [Related]
20. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]